BRPI1015484A2 - derivados de n-[(7-aza-biciclo [2.2.1] hept-1-il)-aril-metil]-benzamida, o respectivo preparo e a respectiva aplicação em terapêutica - Google Patents

derivados de n-[(7-aza-biciclo [2.2.1] hept-1-il)-aril-metil]-benzamida, o respectivo preparo e a respectiva aplicação em terapêutica

Info

Publication number
BRPI1015484A2
BRPI1015484A2 BRPI1015484A BRPI1015484A BRPI1015484A2 BR PI1015484 A2 BRPI1015484 A2 BR PI1015484A2 BR PI1015484 A BRPI1015484 A BR PI1015484A BR PI1015484 A BRPI1015484 A BR PI1015484A BR PI1015484 A2 BRPI1015484 A2 BR PI1015484A2
Authority
BR
Brazil
Prior art keywords
alkyl
alkoxy
arylmethyl
hept
aza
Prior art date
Application number
BRPI1015484A
Other languages
English (en)
Inventor
Geneviève ESTENNE-BOUHTOU
Gihad Dargazanli
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of BRPI1015484A2 publication Critical patent/BRPI1015484A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/14—Nitrogen atoms not forming part of a nitro radical

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Rheumatology (AREA)
  • Psychology (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

derivados de n-[(7-aza-biciclo [2.2.1] hept-1-il)-aril-metil]-benzamida, o respectivo preparo e a respectiva aplicação em terapêutica. na qual : -r representa um átomo de hidrogênio ou um grupo escolhido dentre os grupos (c~ 1~-c~ 6~) alquila, (c~ 3~-c~ 7~)-ciclo alquila, eventualmente substituído por um ou vários grupos escolhidos independentemente um do outro dentre o átomo de flúor, os grupos (c~ 3~-c~ 7~)-ciclo alquila, (c~ 2~-c~ 4~) alcenila, fenila, (c~ 1~-c~ 6~) alcóxi, hidróxi; o grupo fenila é eventualmente substituído por um ou vários grupos (c~ 1~-c~ 6~) alcóxi; -r~ 1~ representa um grupo fenila , eventualmente substituído por um ou vários substituintes escolhidos independentemente um do outro dentre os átomos de halogênio , os grupos (c~ 1~-c~ 6~) alquila, (c~ 1~- c~ 6~) alcóxi, halo-(c~ 1~c~ 6~) alquila, hidróxi, halo-(c~ 1~-c~ 6~) alcóxi, (c~ 1~-c~ 6~) alquila-tio, (c~ 1~-c~ 6~) alquila-so~ 2~;-r~ 2~ representa um ou vários substituintes escolhidos dentre o átomo de hidrogênio, os átomos de halogênio, os grupos halo-(c~ 1~-c~ 6~) alquila, (c~ 1~-c~ 6 ~) alquila, c~ 3~-c~ 7~)-ciclo alquila, (c~ 3~-c~ 7~) alquila, (c~ 1~-c~ 6~) alcóxi, (c~ 1~-c~ 6~) alquil-tio, (c~ 1~-c~ 6~) alquila-so~ 2~; no estado de base ou de sal de adição a um ácido. utilização em terapêutica e processo de síntese.
BRPI1015484A 2009-04-14 2010-04-13 derivados de n-[(7-aza-biciclo [2.2.1] hept-1-il)-aril-metil]-benzamida, o respectivo preparo e a respectiva aplicação em terapêutica BRPI1015484A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0901809A FR2944284A1 (fr) 2009-04-14 2009-04-14 Derives de n-°7-aza-bicyclo°2.2.1!hept-1-yl)-aryl-methyl! -benzamide, leur preparation et leur application en therapeutique
PCT/FR2010/050711 WO2010119222A1 (fr) 2009-04-14 2010-04-13 Derives de n-[(7-aza-bicyclo[2.2.1]hept-1-yl)-aryl-methyl]-benzamide, leur preparation et leur application en therapeutique

Publications (1)

Publication Number Publication Date
BRPI1015484A2 true BRPI1015484A2 (pt) 2016-04-26

Family

ID=41228015

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1015484A BRPI1015484A2 (pt) 2009-04-14 2010-04-13 derivados de n-[(7-aza-biciclo [2.2.1] hept-1-il)-aril-metil]-benzamida, o respectivo preparo e a respectiva aplicação em terapêutica

Country Status (14)

Country Link
EP (1) EP2419431A1 (pt)
JP (1) JP2012523448A (pt)
KR (1) KR20120013378A (pt)
AR (1) AR076276A1 (pt)
AU (1) AU2010238409A1 (pt)
BR (1) BRPI1015484A2 (pt)
CA (1) CA2758367A1 (pt)
FR (1) FR2944284A1 (pt)
IL (1) IL215673A0 (pt)
MX (1) MX2011010929A (pt)
SG (1) SG175222A1 (pt)
TW (1) TW201041581A (pt)
UY (1) UY32561A (pt)
WO (1) WO2010119222A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20160045182A (ko) 2014-10-16 2016-04-27 현대자동차주식회사 실린더 라이너용 회주철 및 이를 이용한 실린더 라이너의 제조방법

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2842804B1 (fr) * 2002-07-29 2004-09-03 Sanofi Synthelabo Derives de n-[phenyl(piperidin-2-yl)methyl]benzamide, leur preparation et leur application en therapeutique
FR2861076B1 (fr) * 2003-10-17 2006-01-06 Sanofi Synthelabo Derives de n-heterocyclymethylbenzamide, leur preparation et leur application en therapeutique
WO2008065500A2 (en) * 2006-11-30 2008-06-05 Pfizer Products Inc. Heteroaryl amides as type i glycine transport inhibitors
TW200911808A (en) * 2007-07-23 2009-03-16 Astrazeneca Ab Novel compounds

Also Published As

Publication number Publication date
AU2010238409A1 (en) 2011-11-03
SG175222A1 (en) 2011-11-28
TW201041581A (en) 2010-12-01
IL215673A0 (en) 2012-01-31
WO2010119222A1 (fr) 2010-10-21
MX2011010929A (es) 2011-11-02
UY32561A (es) 2010-11-30
CA2758367A1 (fr) 2010-10-21
EP2419431A1 (fr) 2012-02-22
FR2944284A1 (fr) 2010-10-15
AR076276A1 (es) 2011-06-01
JP2012523448A (ja) 2012-10-04
KR20120013378A (ko) 2012-02-14

Similar Documents

Publication Publication Date Title
CY1124357T1 (el) Προσδιορισμος ανισορροπιας αλληλουχιας νουκλεϊκων οξεων
BRPI0814153B8 (pt) Método para preparar derivados de 5-haloalquil-4,5-diidroisoxazol e compostos de partida úteis no método
AR058701A1 (es) Derivados de piracinil-s-espiro-oxacinoquinolin-pirimidin-triona como agentes antibacterianos
ATE431345T1 (de) Als modulatoren von dopamin-d3-rezeptoren geeignete azabicyclo-(3,1,0)-hexan-derivate
EA201101089A1 (ru) Производные оксадиазола в качестве агонистов рецептора s1p1
BRPI0606806A2 (pt) compostos indólicos, suas composições e seus usos
CY1111671T1 (el) Ετεροκυκλικη ενωση
EA200901187A1 (ru) Диаминопиримидины в качестве фунгицидов
EA200970569A1 (ru) Применимые в качестве гербицидных соединений пиридопиразиновые производные
BRPI0608732A2 (pt) composto ou um sal, hidrato, solvato, complexo ou pró-droga farmaceuticamente aceitável do mesmo, sal de um composto, processo para a preparação de um composto, uso de um composto, composição farmacêutica, e, produto
BRPI0507054A (pt) bloqueadores do canal de cálcio tipo n
MA32192B1 (fr) Composés dérivés d'azétidines, leur préparation et leur application en thérapeutique
BR112013001341A2 (pt) compostos de pirimidina como inibidores de proteínas quinases ikk épsilon e/ou tbk-1, processo para a preparação dos mesmos e suas composições farmacêuticas
NO20072409L (no) Substituerte n-sulfonylaminobenzyl-2-fenoksy acetamid-forbindelser
BRPI0510399A (pt) processo de preparo de derivados n-piperidino-1,5-difenilpirazol-3-carboxamida
TW200715973A (en) Use of phenylsemicarbazones for seed treatment
BRPI1009497A2 (pt) Derivados de n-[(6-aza-biciclo[3.2.1] oct-5-il)-aril- metil]-heterobenzamida, o respectivo preparo e a respectiva aplicação em terapêutica
BR0208812A (pt) Derivados fenil heterociclil éter como inibidores de recaptação de serotonina
EA200700767A1 (ru) Способ получения пиразолов
BRPI1015484A2 (pt) derivados de n-[(7-aza-biciclo [2.2.1] hept-1-il)-aril-metil]-benzamida, o respectivo preparo e a respectiva aplicação em terapêutica
BRPI0416678A (pt) pirazolpirimidinas
BRPI0514020A (pt) oxindóis oxazolidinonas como agentes antibacterianos
BRPI0413741A (pt) métodos para preparar thip e para preparar um composto, e, composto
DE602004031878D1 (de) Immunhemmende pyrazolon-verbindungen
ECSP088170A (es) Derivados de 5-piridinil-1-azabiciclo[3.2.1]octano, su preparación y su aplicación en terapéutica

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]